VIP and Bronchodilation: An Asthma Peptide Target
Neuropeptides in Airway Disease
100x more potent
VIP relaxes human bronchial smooth muscle 100 times more potently than isoproterenol, the standard beta-agonist comparator, making it the most potent endogenous bronchodilator identified.
Said, American Journal of Respiratory Cell and Molecular Biology, 2008
Said, American Journal of Respiratory Cell and Molecular Biology, 2008
View as imageVasoactive intestinal peptide (VIP) was first isolated from pig intestine in 1970, but its most dramatic biological property is in the lungs: it is the most potent endogenous bronchodilator ever identified, approximately 100 times more effective at relaxing airway smooth muscle than isoproterenol.[1] VIP also suppresses airway inflammation, inhibits mast cell degranulation, and modulates immune cell trafficking. On paper, it is the perfect asthma drug. In practice, it has never become one. The reasons for that gap, rapid enzymatic degradation, systemic side effects, and formulation challenges, tell a broader story about why potent biological peptides often fail to translate into therapeutics. This article traces VIP's bronchodilatory evidence from the first human trials in 1983 to the ongoing efforts to develop stable VIP analogs. For context on how neurogenic inflammation drives asthma attacks, see our pillar article on airway neuropeptides.
Key Takeaways
- VIP caused significant bronchodilation in asthmatic patients when infused intravenously at 6 pmol/kg/min, with a peak expiratory flow rate increase of 26 L/min[2]
- VIP protected against histamine-induced bronchoconstriction in all seven asthmatic subjects tested in a double-blind study[3]
- VIP's plasma half-life is approximately 2 minutes due to rapid degradation by tryptase, chymase, and neutral endopeptidase, making systemic delivery impractical[4]
- VIP signals through VPAC1 and VPAC2 receptors; VPAC2-deficient mice develop exacerbated autoimmune inflammation with increased Th1/Th17 responses[5]
- VIP-deficient mice develop spontaneous pulmonary arterial hypertension with vascular remodeling and airway inflammation[1]
- Inhaled VIP (aviptadil) reduced pulmonary artery pressure by 10% in pulmonary hypertension patients without systemic side effects[6]
The First Human Bronchodilation Trials
The earliest evidence that VIP could dilate human airways came from Morice et al. in 1983, published in The Lancet.[3] Seven asthmatic volunteers received intravenous VIP at 6 pmol/kg/min for 15 minutes in a double-blind, placebo-controlled design. VIP caused significant bronchodilation, and every subject showed protection against subsequent histamine-induced bronchoconstriction. The catch: all subjects experienced tachycardia and cutaneous flushing during the infusion, reflecting VIP's potent vasodilatory effects.
Morice followed up in 1986 with a study in patients recovering from severe acute asthma.[2] Two groups of eight inpatients received VIP infusions at the same dose. Peak expiratory flow rate (PEFR) increased by 26 L/min after 30 minutes of VIP infusion compared to 39 L/min with salbutamol, the standard beta-agonist. VIP worked, but it was less effective than the existing treatment and caused more side effects.
These two studies established VIP's credentials as a bronchodilator while simultaneously revealing why it would be difficult to develop as a drug. The peptide dilated every smooth muscle it encountered, not just airway smooth muscle, producing cardiovascular effects that limited the therapeutic window.
VIP's Dual Mechanism in Airways
VIP acts on two fronts in the respiratory system: direct smooth muscle relaxation and immune modulation. This dual action distinguishes it from conventional bronchodilators like salbutamol, which primarily target beta-2 adrenergic receptors on smooth muscle.
Bronchodilation
VIP relaxes airway smooth muscle by binding VPAC2 receptors, activating adenylate cyclase, and increasing intracellular cAMP. This is mechanistically similar to beta-2 agonists but operates through a different receptor pathway. The potency advantage (100-fold over isoproterenol) reflects VIP's direct action on airway smooth muscle without requiring sympathetic nervous system intermediaries.[1]
Anti-Inflammatory Effects
Delgado et al. (2013) described VIP's anti-inflammatory actions in detail: it inhibits production of TNF-alpha, IL-6, and IL-12 while stimulating IL-10 production; it suppresses NF-kB activation in macrophages; and it promotes regulatory T cell differentiation over inflammatory Th17 responses.[4] Ganea et al. (2015) showed that VIP's effects are mediated primarily through VPAC1 on immune cells, with downstream suppression of pro-inflammatory gene transcription.[7]
For asthma, where both bronchoconstriction and airway inflammation drive symptoms, a molecule that addresses both simultaneously is theoretically ideal. The pro-inflammatory neuropeptides substance P and CGRP promote the very inflammation that VIP suppresses, creating a neuropeptide balance in the airways where VIP acts as the natural brake.
VPAC1 and VPAC2: The Receptor Biology
VIP signals through two G-protein coupled receptors: VPAC1 and VPAC2. Their tissue distribution determines which VIP effects predominate in different contexts.
VPAC1 is abundant in lung tissue and T-lymphocytes. It mediates most of VIP's anti-inflammatory effects. Abad et al. (2016) showed that VPAC1-deficient mice developed altered inflammatory responses, confirming the receptor's role as an immune modulator.[8]
VPAC2 is concentrated in airway smooth muscle, mast cells, and the basal lung mucosa. It drives bronchodilation. Tan et al. (2015) demonstrated that VPAC2-deficient mice developed exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 responses and reduced Th2/Treg populations, showing that VPAC2 also contributes to immune regulation beyond the lungs.[9]
This receptor distribution has driven drug design strategy. A selective VPAC2 agonist would theoretically provide bronchodilation with less of the vasodilation and systemic immune effects mediated by VPAC1. The peptide analog Ro25-1553 was designed with this rationale: in a trial of 24 patients with moderate stable asthma, inhaled Ro25-1553 produced rapid-onset bronchodilation without adverse effects.[10] The effect was potent but short-lived, reflecting the same metabolic instability problem that limits native VIP.
Why VIP Has Not Become an Asthma Drug
Metabolic Instability
VIP's plasma half-life is approximately 2 minutes. It is rapidly cleaved by tryptase (released from mast cells during asthma attacks), chymase, and neutral endopeptidase (abundant on airway epithelial cells). This means the peptide is destroyed fastest precisely where it is needed most: in inflamed asthmatic airways where mast cell tryptase concentrations are elevated.[4]
Atanasova et al. (2018) noted that this degradation creates a paradox in asthma: VIP levels in bronchial tissue are reduced in asthmatic patients compared to healthy controls, likely because enzymatic degradation exceeds production during chronic inflammation.[10] The peptide that should be protecting the airways is being destroyed by the disease itself.
Systemic Side Effects
VIP dilates blood vessels as potently as it dilates bronchi. Intravenous administration produces hypotension, tachycardia, and flushing at doses needed for bronchodilation. This makes systemic delivery impractical. Inhaled delivery avoids systemic exposure but faces its own challenge: the peptide must survive in airway fluid long enough to reach smooth muscle receptors.
Formulation Challenges
Standard dry powder or metered-dose inhalers are designed for small, stable molecules. A 28-amino-acid peptide that degrades in minutes requires specialized formulation. Efforts have included liposomal encapsulation, PEGylation, and the development of metabolically stable analogs. None has yet produced a commercially viable inhaler for asthma.
VIP Beyond Asthma: Pulmonary Hypertension and COVID-19
Pulmonary Hypertension
Said (2008) demonstrated that VIP-deficient mice spontaneously develop pulmonary arterial hypertension (PAH) with vascular remodeling and perivascular inflammation, establishing VIP as an endogenous PAH-protective factor.[1] Human studies followed: Leuchte et al. (2008) tested inhaled VIP (aviptadil) in PAH patients and found it reduced pulmonary artery pressure by approximately 10% and improved cardiac output, with no systemic side effects.[6] Inhaled delivery bypassed the systemic vasodilation problem that plagued intravenous studies.
Chen et al. (2025) showed that VIP expression is critical for normal fetal lung development, with VIP analog aviptadil partially rescuing lung hypoplasia in a congenital diaphragmatic hernia animal model.[11] This underscores VIP's fundamental role in lung biology beyond its acute bronchodilatory effects.
COVID-19 ARDS
During the COVID-19 pandemic, VIP gained attention as a potential treatment for acute respiratory distress syndrome (ARDS). Gutzler et al. (2025) showed that VIP promoted shedding of ACE2 and TMPRSS2 via ADAM10 metalloproteinase, potentially reducing viral entry while simultaneously suppressing the cytokine storm response.[12] Intravenous aviptadil was tested in clinical trials for COVID-19 ARDS, with early reports suggesting improved oxygenation and reduced inflammatory markers, though definitive phase 3 results have not confirmed a survival benefit.
For related work on how VIP interacts with other neuropeptide systems, see our article on peptide approaches to COPD, where VIP's role in chronic airflow obstruction is distinct from its acute bronchodilatory effects.
Stable VIP Analogs and Future Directions
The search for a metabolically stable VIP analog that retains bronchodilatory potency without systemic vasodilation has been ongoing for over three decades. Several strategies have been explored:
Selective VPAC2 agonists target the bronchodilatory receptor while avoiding VPAC1-mediated immune effects. Ro25-1553 demonstrated proof-of-concept but was not developed further due to its short duration of action.
Modified peptide backbones using D-amino acid substitutions, N-methylation, or cyclization can resist protease degradation. These modifications sometimes reduce receptor affinity, creating an optimization problem.
Nanoparticle encapsulation protects VIP from enzymatic degradation and can provide sustained release in the airways. This approach has shown promise in preclinical models but has not reached clinical trials for asthma.
Gene therapy approaches targeting VIP expression in airway neurons represent a longer-term strategy. If endogenous VIP production could be restored or enhanced in asthmatic airways, the delivery and stability problems would be bypassed entirely.
The broader VIP research community has expanded beyond the lungs. Fan et al. (2025) reviewed VIP's neuroprotective role in Parkinson's disease, illustrating that the same peptide's pleiotropic actions create therapeutic opportunities across multiple organ systems.[13] Each application faces the same fundamental challenge: delivering a fragile 28-amino-acid peptide to its target tissue in sufficient quantity and for sufficient duration. For asthma, that challenge intersects with a disease market dominated by cheap, effective, and stable small-molecule bronchodilators, making the commercial case for VIP-based therapy particularly difficult. The peptide's potential role in anti-inflammatory approaches beyond the airways also remains under active investigation.
The Bottom Line
VIP is the most potent endogenous bronchodilator known, approximately 100 times more effective than isoproterenol at relaxing airway smooth muscle. Human trials in the 1980s confirmed bronchodilation in asthmatic patients, but the peptide's 2-minute half-life, systemic vasodilatory effects, and destruction by the very enzymes elevated in asthmatic airways have prevented its development as a drug. Selective VPAC2 agonists, inhaled delivery (successful in pulmonary hypertension), and stable peptide analogs represent the most viable paths forward. None has yet produced an approved asthma therapy.